Kewalramani Reshma 4: 4,981 shares of VRTX ($2,416,332)

Our Take

→Vertex's CEO dumping $2.4M in stock—roughly 15% of her direct holdings—suggests confidence in near-term valuation rather than distress, especially given her substantial remaining position. For a biotech CEO, this scale of sale is routine portfolio rebalancing rather than a flight signal. The timing matters: Vertex has had a strong run on CASGEVY approval momentum and expanded CF market penetration, so selling into strength is textbook executive behavior.